3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
133
Squamous Cell Carcinoma of Head and Neck
75
Lung Neoplasms
48
Head and Neck Neoplasms
45
Urinary Bladder Neoplasms
43
Parkinson Disease 4, Autosomal Dominant Lewy Body
33
Oropharyngeal Neoplasms
32
Nasopharyngeal Carcinoma
31
Biliary Tract Neoplasms
31
Uterine Cervical Neoplasms
29
Cholangiocarcinoma
29
Neoplasms
24
Esophageal Squamous Cell Carcinoma
24
Carcinoma
24
Neoplasm Metastasis
23
Small Cell Lung Carcinoma
21
Ovarian Neoplasms
21
Carcinoma, Squamous Cell
20
Colorectal Neoplasms
19
Stomach Neoplasms
18
Pancreatic Neoplasms
17
Carcinoma, Transitional Cell
17
Esophageal Neoplasms
16
Mesothelioma, Malignant
15
Gallbladder Neoplasms
15
Mouth Neoplasms
14
Laryngeal Neoplasms
13
Hypopharyngeal Neoplasms
12
Endometrial Neoplasms
11
Triple Negative Breast Neoplasms
10
Interventions
pembrolizumab
4
Nivolumab
4
fludarabine
3
aldesleukin
3
Ipilimumab
3
Cyclophosphamide
3
vedolizumab
2
enfortumab vedotin
2
darolutamide
2
cabozantinib
2
atezolizumab
2
Specimen Handling
2
Riluzole
2
Prednisone
2
Magnetic Resonance Spectroscopy
2
LDP-02
2
Infliximab
2
Immunoglobulin G
2
Fecal Microbiota Transplantation
2
Disulfides
2
CTLA-4 Antigen
2
CT-P13
2
Biopsy
2
relatlimab
1
prednylidene
1
palbociclib
1
olaparib
1
gallium 68 PSMA-11
1
deltacortene
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urogenital Neoplasms
×
Cisplatin
×
1 year
×
Clear all
NCT07566156
2026-06-08
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled